Rascón-Martínez Dulce M, Ullah Samid, Memon Muhammad Anwar, Bangash Adil, Ali Ayub, Ikram Ul Haq Muhammad, Mohyuddin Arif, Khan Muhammad Kamran, Ovais Fatima, Mustafa Imtiaz
Anesthesia, Instituto Mexicano del Seguro Social (IMSS), Mexico City, MEX.
Gastroenterology and Hepatology, Khalifa Gul Nawaz Teaching Hospital, Medical Teaching Institution Bannu, Bannu, PAK.
Cureus. 2025 Jan 7;17(1):e77117. doi: 10.7759/cureus.77117. eCollection 2025 Jan.
Introduction Patients with hepatic dysfunction undergoing general surgery face significant perioperative risks due to the liver's critical role in drug metabolism and systemic homeostasis. Opioid-sparing techniques may mitigate these risks by reducing opioid consumption and minimizing hepatic complications. Objective The objective of the study was to evaluate the effectiveness of opioid-sparing techniques in pain management for general surgery patients with hepatic dysfunction and their impact on postoperative outcomes. Methodology This observational cohort study was conducted at Lady Reading Hospital, Peshawar, Pakistan, from November 2023 to October 2024. A total of 100 patients with hepatic dysfunction undergoing elective general surgeries were included, with 50 managed using opioid-sparing techniques and 50 receiving opioid-based analgesia. Pain was assessed using the Numeric Rating Scale (NRS) at six, 12, 24, and 48 hours post-surgery. Opioid consumption was quantified as morphine-equivalent doses over 48 hours. Hepatic function parameters (aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin) and postoperative outcomes, including complications and hospital stay, were analyzed. Results Postoperative pain scores were significantly lower in the opioid-sparing group across all time points (e.g., NRS at six hours: 2.9 ± 0.8 vs. 4.5 ± 1.1, p < 0.001). Opioid consumption was reduced by 67% in the opioid-sparing group (4.1 ± 1.5 mg vs. 12.6 ± 3.8 mg,p < 0.001). Hepatic function parameters remained stable in both groups. The opioid-sparing group had shorter hospital stays (3.8 ± 0.9 days vs. 5.1 ± 1.2 days, p < 0.001) and fewer complications, including nausea (12% vs. 30%, p = 0.02) and respiratory depression (0% vs. 10%, p = 0.04). Conclusion Opioid-sparing techniques improve pain management, reduce opioid consumption, and minimize postoperative complications in patients with hepatic dysfunction undergoing general surgery. These findings support incorporating opioid-sparing protocols into perioperative care for this high-risk population.
由于肝脏在药物代谢和全身稳态中起着关键作用,肝功能不全的患者在接受普通外科手术时面临重大的围手术期风险。阿片类药物节省技术可以通过减少阿片类药物的使用和将肝脏并发症降至最低来减轻这些风险。
本研究的目的是评估阿片类药物节省技术在肝功能不全的普通外科手术患者疼痛管理中的有效性及其对术后结局的影响。
本观察性队列研究于2023年11月至2024年10月在巴基斯坦白沙瓦的雷丁夫人医院进行。共有100例接受择期普通外科手术的肝功能不全患者被纳入研究,其中50例采用阿片类药物节省技术进行管理,50例接受基于阿片类药物的镇痛。术后6小时、12小时、24小时和48小时使用数字评分量表(NRS)评估疼痛。阿片类药物的消耗量以48小时内的吗啡当量剂量进行量化。分析肝功能参数(天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和总胆红素)以及术后结局,包括并发症和住院时间。
在所有时间点,阿片类药物节省组的术后疼痛评分均显著较低(例如,6小时时的NRS:2.9±0.8 vs. 4.5±1.1,p<0.001)。阿片类药物节省组的阿片类药物消耗量减少了67%(4.1±1.5 mg vs. 12.6±3.8 mg,p<0.001)。两组的肝功能参数均保持稳定。阿片类药物节省组的住院时间较短(3.8±0.9天 vs. 5.1±1.2天,p<0.001),并发症较少,包括恶心(12% vs. 30%,p = 0.02)和呼吸抑制(0% vs. 10%,p = 0.04)。
阿片类药物节省技术可改善肝功能不全的普通外科手术患者的疼痛管理,减少阿片类药物的使用,并将术后并发症降至最低。这些发现支持将阿片类药物节省方案纳入这一高危人群的围手术期护理中。